BlackRock Debt Strategies Fund (DSU) offers a high yield of 13.7%, driven by its focus on floating-rate senior loans and a short duration portfolio. Currently, DSU trades at a 6.7% discount to its net asset value (NAV), which is within its historical range, with a negative one-year Z-score of -2.26. The fund uses leverage (17.8%) and has significant credit exposure, which boosts yield but also increases volatility and risk, especially if interest rates fall. While DSU can provide stable long-term returns, investors should carefully consider credit and interest rate risks before buying at the current discount.
The BlackRock Debt Strategies Fund (DSU) features a high yield of 13.7%, offering context for readers interested in this fund. For readers following US stocks on Pluang, here is the market snapshot as of Oct 23, 2026 16:01 WIB: out of 150 priced US stocks, 55 rose and 83 fell. Notable movers include Verizon Communications Inc (VZ) at USD 43.72 with a 1-day change of -3.27% and Pluang order activity showing 63% Sell / 37% Buy, Norwegian Cruise Line Holdings Ltd (NCLH) at USD 15.10 down 2.83%, and Firy Inc. (FIRY) at USD 11.32 down 2.58%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
